Development of medical therapeutics in osteoarthritis: time for action to improve patient care
Rheumatology (Oxford)
.
2021 Aug 2;60(8):3487-3489.
doi: 10.1093/rheumatology/keab263.
Authors
Nidhi Sofat
1
2
,
Fiona E Watt
3
,
Ai Lyn Tan
4
5
Affiliations
1
Institute for Infection and Immunity, St George's, University of London, London, UK.
2
Department of Rheumatology, St George's, University Hospitals NHS Foundation Trust, London, UK.
3
Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, UK.
4
NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
5
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
PMID:
33715006
PMCID:
PMC8328507
DOI:
10.1093/rheumatology/keab263
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
Drug Development*
Humans
Osteoarthritis / drug therapy*
Grants and funding
MR/S016538/1/MRC_/Medical Research Council/United Kingdom
MR/S016538/2/MRC_/Medical Research Council/United Kingdom